RC18 240mg ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎1
66IgA腎症1

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04625153
(ClinicalTrials.gov)
June 2, 20216/11/2020RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II TrialRC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II TrialMultiple Sclerosis, Relapsing-RemittingBiological: RC18 160mg;Biological: RC18 240mgRemeGen Co., Ltd.NULLRecruiting18 Years55 YearsAll18Phase 2China

66. IgA腎症


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04291781
(ClinicalTrials.gov)
April 13, 202027/2/2020A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) NephropathyPhase II Clinical Trial of RC18(Recombinant Human B Lymphocyte Stimulator Receptor - Antibody Fusion Protein for Injection) in the Treatment of IgA NephropathyIgA NephropathyBiological: RC18 160mg;Biological: RC18 240mg;Biological: placeboRemeGen Co., Ltd.NULLCompleted18 Years70 YearsAll44Phase 2China